Reviewing Avalon GloboCare (CHGA) & The Competition

Avalon GloboCare (NASDAQ:CHGA) is one of 954 publicly-traded companies in the “Software” industry, but how does it contrast to its competitors? We will compare Avalon GloboCare to similar companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.

Earnings and Valuation

This table compares Avalon GloboCare and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Avalon GloboCare	$1.26 million	-$18.26 million	-0.10
Avalon GloboCare Competitors	$1.79 billion	$385.13 million	111.21

Avalon GloboCare’s competitors have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Avalon GloboCare has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Avalon GloboCare’s competitors have a beta of 1.25, indicating that their average share price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Avalon GloboCare and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1	0	0	0	1.00
Avalon GloboCare Competitors	5714	21419	44677	1492	2.57

As a group, “Software” companies have a potential upside of 27.83%. Given Avalon GloboCare’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Avalon GloboCare has less favorable growth aspects than its competitors.

Profitability

This table compares Avalon GloboCare and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-53.69%
Avalon GloboCare Competitors	-612.31%	21.01%	-8.89%

Insider and Institutional Ownership

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 41.8% of shares of all “Software” companies are owned by institutional investors. 16.8% of Avalon GloboCare shares are owned by insiders. Comparatively, 19.9% of shares of all “Software” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Avalon GloboCare competitors beat Avalon GloboCare on 12 of the 13 factors compared.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.